EPH Receptor B4 Antikörper

Produktnummer ABIN969107

Produktdetails anti-EPH Receptor B4 Antikörper

Target: EPH Receptor B4 (EPHB4)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EPH Receptor B4 Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC)

Verwendungszweck: EphB4 Antibody

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of EphB4 expressed in E. Coli.

Klon: 5B8F7

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: ELISA: 1/10000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-EPH Receptor B4 Antikörper (ABIN969107)

Chrencik, Brooun, Recht, Kraus, Koolpe, Kolatkar, Bruce, Martiny-Baron, Widmer, Pasquale, Kuhn: "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity." in: Structure (London, England : 1993), Vol. 14, Issue 2, pp. 321-30, (2006) (PubMed).

Wu, Suo, Risberg, Karlsson, Villman, Nesland: "Expression of Ephb2 and Ephb4 in breast carcinoma." in: Pathology oncology research : POR, Vol. 10, Issue 1, pp. 26-33, (2004) (PubMed).

Details zu EPH Receptor B4

Target: EPH Receptor B4 (EPHB4)

Andere Bezeichnung: EphB4 (EPHB4 Produkte)

Hintergrund:

Description: EPH receptor B4 (EphB4), with 987-amino acid protein (about 108 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. The Eph receptor tyrosine kinases and their ligands, the ephrins, regulate numerous biological processes in developing and adult tissues and have been implicated in cancer progression and in pathological forms of angiogenesis. EphB4 acts as a negative regulator of blood vessel branching and vascular network formation, switching the vascularization program from sprouting angiogenesis to circumferential vessel growth. EphB4 and its ligand ephrinB2 express in several kinds of tumor cells and correlate with tumorigenesis. EphB4 is thus a potential candidate as a predictor of disease outcome in several kinds of tumor and as target for novel therapy.

Aliases: HTK, MYK1, TYRO11

Gen-ID: 2050

HGNC: 2050

UniProt: P54760

Pathways: RTK Signalweg